Gritstone bio Inc. (NASDAQ:GRTS) shares are trading lower by 64.2% to $0.07 during Thursday's session after the company announced it voluntarily filed for Chapter 11 restructuring.What Else: Gritstone Bio says the company plans to use the court-supervised restructuring to preserve value while exploring strategic ...Full story available on Benzinga.com
Gritstone Bio is a California-based biotechnology company that develops and commercializes immunotherapies for the treatment of cancer and infectious diseases.